--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-24-047020" form_type: "8-K" ticker: "RNLXY" cik: "0001811115" company_name: "Renalytix plc" filed_at: "2024-04-23T23:59:59+00:00" generated_at: "2026-06-03T12:12:15.699416+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded ## Summary - Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options. - Howard Doran appointed President effective April 30, 2024; base salary increased to $350K from $300K. - Investor DB Capital exercised option to buy 1,333,334 additional shares at $0.375/share, raising net ~$0.5M. - Shareholders approved allotment of up to 26.8M new ordinary shares and related pre-emptive waivers with >98% support. - Original option exercise period extended to April 22, 2024 via letter agreement; total offering includes 4M shares at $0.375. ## SEC filing metadata - accession: 0000950170-24-047020 - form_type: 8-K - ticker: RNLXY - cik: 0001811115 - company_name: Renalytix plc - filed_at: 2024-04-23T23:59:59+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 1.01, 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/rnlx-20240417.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-24-047020 - JSON: https://secwatch.observer/filing/0000950170-24-047020.json - Plain text: https://secwatch.observer/filing/0000950170-24-047020.txt ## Key facts - Executive change Thomas McLain resigned as President at Renalytix plc. - Action: resigned - Role: President source text: On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - Executive change Howard Doran was appointed as President at Renalytix plc. - Action: appointed - Role: President source text: On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - Material Agreements Renalytix plc entered into Purchase Agreement with DB Capital Partners Healthcare, L.P. (effective 2024-04-05). - Action: entry - Agreement: equity purchase - Counterparty: DB Capital Partners Healthcare, L.P. - Effective: 2024-04-05 source text: on April 5, 2024, Renalytix plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with DB Capital Partners Healthcare, L.P. (the “ Purchaser ”) evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - Shareholder Votes Renalytix plc shareholders approved Authorization of disapplication of pre-emption rights limited to shares of maximum aggregate nominal amount of £128,391 at the 2024-04-22 meeting. - Outcome: passed - Meeting: 2024-04-22 source text: Proposal 4 – Subject to and conditional upon the passing of Proposal 2, to authorize the disapplication of pre-emption rights limited to shares of a maximum aggregate nominal amount of £128,391. For Against Vote Withheld 45,853,622 4,859,914 120,004 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - Shareholder Votes Renalytix plc shareholders approved Authorization of allotment of shares and grant of rights to subscribe for or convert into shares up to aggregate nominal amount of £128,391 and further allotment in connection with pre-emptive offer at the 2024-04-22 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2024-04-22 source text: Proposal 2 – To authorize the allotment of shares and the grant of rights to subscribe for, or convert any security into, shares of the Company up to an aggregate nominal amount of £128,391 and the allotment of further equity securities up to an aggregate nominal amount of £122,277 in connection with a pre-emptive offer in favor of shareholders. For Against Vote Withheld 45,880,130 4,832,979 120,431 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - Shareholder Votes Renalytix plc shareholders approved Authorization of allotment of ordinary shares up to aggregate nominal amount of £67,039.6025 (Second Tranche Placing Shares) at the 2024-04-22 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2024-04-22 source text: Proposal 1 – To authorize the al lotment of ordinary shares of £0.0025 each in the capital of the Company up to an aggregate nominal amount of £67,039.6025 (26,815,841 ordinary shares) (the “Second Tranche Placing Shares”). For Against Vote Withheld 50,091,780 621,329 120,431 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm - Shareholder Votes Renalytix plc shareholders approved Authorization of disapplication of statutory pre-emption rights for Second Tranche Placing Shares and shareholder approval pursuant to Nasdaq 20% Rule at the 2024-04-22 meeting. - Outcome: passed - Meeting: 2024-04-22 source text: Proposal 3 – Subject to and conditional upon the passing of Proposal 1, to authorize (i) the disapplication of statutory pre-emption rights for the issue and allotment of the Second Tranche Placing Shares and (ii) shareholder approval pursuant to the Nasdaq 20% Rule. For Against Vote Withheld 50,072,092 641,404 120,044 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.